

# Nir Eyal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7687025/publications.pdf>

Version: 2024-02-01

97  
papers

1,634  
citations

430874

18  
h-index

345221

36  
g-index

100  
all docs

100  
docs citations

100  
times ranked

2527  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants. <i>Journal of Infectious Diseases</i> , 2022, 225, 934-937.	4.0	3
2	Do coronavirus vaccine challenge trials have a distinctive generalisability problem?. <i>Journal of Medical Ethics</i> , 2022, 48, 586-589.	1.8	6
3	“The research assistants kept coming to follow me up; I counted myself as a lucky person” Social support arising from a longitudinal HIV cohort study in Uganda. <i>PLoS ONE</i> , 2022, 17, e0262989.	2.5	2
4	Pandemic vaccine testing: Combining conventional and challenge studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, , .	1.9	2
5	A new day for human challenge trials?. <i>Trends in Molecular Medicine</i> , 2022, , .	6.7	0
6	Coronavirus Disease 2019 (COVID-19) Vaccine Prioritization in Low- and Middle-Income Countries May Justifiably Depart From High-Income Countries’™ Age Priorities. <i>Clinical Infectious Diseases</i> , 2022, 75, S93-S97.	5.8	2
7	One lesson of COVID-19: Conduct more health policy trials. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	3
8	Broad cross-national public support for accelerated COVID-19 vaccine trial designs. <i>Vaccine</i> , 2021, 39, 309-316.	3.8	11
9	Rescuing Vapers Versus Rescuing Smokers: The Ethics. <i>Nicotine and Tobacco Research</i> , 2021, 23, 26-31.	2.6	8
10	Electronic Adherence Monitoring May Facilitate Intentional HIV Status Disclosure Among People Living with HIV in Rural Southwestern Uganda. <i>AIDS and Behavior</i> , 2021, 25, 2131-2138.	2.7	8
11	How to Test Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines Ethically Even After One Is Available. <i>Clinical Infectious Diseases</i> , 2021, 73, 2332-2334.	5.8	9
12	Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure. <i>Clinical Microbiology and Infection</i> , 2021, 27, 372-377.	6.0	10
13	COVID vaccine efficacy against the B.1.351 (“South African”) variant”The urgent need to lay the groundwork for possible future challenge studies. <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-2.	3.3	5
14	Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies. <i>International Journal of Infectious Diseases</i> , 2021, 105, 307-311.	3.3	8
15	COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement. <i>Journal of Medical Ethics</i> , 2021, 47, 539-542.	1.8	4
16	Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests. <i>Vaccine</i> , 2021, 39, 3455-3458.	3.8	3
17	“Thought provoking”, “interactive”, and “more like a peer talk”: Testing the deliberative interview style in Germany. <i>SSM Qualitative Research in Health</i> , 2021, 1, 100007.	1.5	2
18	From Doxastic to Epistemic: A Typology and Critique of Qualitative Interview Styles. <i>Qualitative Inquiry</i> , 2020, 26, 291-305.	1.4	32

#	ARTICLE	IF	CITATIONS
19	“Cure” Versus “Clinical Remission”: The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication. <i>AIDS and Behavior</i> , 2020, 24, 2054-2061.	2.7	7
20	Reply to Hasford and to Spinola et al. <i>Journal of Infectious Diseases</i> , 2020, 222, 1574-1575.	4.0	0
21	Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines. <i>Journal of Medical Ethics</i> , 2020, 46, 808-812.	1.8	15
22	AIDS Activism and Coronavirus Vaccine Challenge Trials. <i>AIDS and Behavior</i> , 2020, 24, 3302-3305.	2.7	7
23	Unnecessary hesitancy on human vaccine tests. <i>Science</i> , 2020, 369, 150-151.	12.6	4
24	Opinion: It’s ethical to test promising coronavirus vaccines against less-promising ones. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18898-18901.	7.1	1
25	Study bystanders and ethical treatment of study participants—A proof of concept. <i>Bioethics</i> , 2020, 34, 941-947.	1.4	1
26	Symposium on risks to bystanders in clinical research: An introduction. <i>Bioethics</i> , 2020, 34, 879-882.	1.4	4
27	Is There an Ethical Upper Limit on Risks to Study Participants?. <i>Public Health Ethics</i> , 2020, 13, 143-156.	1.0	3
28	Response to Dawson et al. <i>Journal of Infectious Diseases</i> , 2020, 222, 516-517.	4.0	2
29	Response to Cioffi. <i>Journal of Infectious Diseases</i> , 2020, 222, 169-170.	4.0	6
30	Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. <i>Journal of Infectious Diseases</i> , 2020, 221, 1752-1756.	4.0	186
31	On Knowingly Setting Unrealistic Goals in Public Health. <i>American Journal of Public Health</i> , 2020, 110, 480-484.	2.7	6
32	Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events. <i>Ethics &amp; Human Research</i> , 2020, 42, 24-34.	0.9	23
33	Ethical complexities of responding to bystander risk in HIV prevention trials. <i>Clinical Trials</i> , 2019, 16, 458-460.	1.6	2
34	Regulating impact on bystanders in clinical trials: An unsettled frontier. <i>Clinical Trials</i> , 2019, 16, 450-454.	1.6	8
35	Is it ethical to isolate study participants to prevent HIV transmission during trials with an analytical treatment interruption?. <i>Journal of Infectious Diseases</i> , 2019, 220, S19-S21.	4.0	5
36	Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium. <i>Journal of Infectious Diseases</i> , 2019, 220, S1-S4.	4.0	21

#	ARTICLE	IF	CITATIONS
37	Removing One Barrier to Protecting Sex Partners in HIV Remission Studies With a Treatment Interruption. <i>Journal of Infectious Diseases</i> , 2019, 220, S22-S23.	4.0	5
38	How to Address the Risk of HIV Transmission in Remission Studies With Treatment Interruption: The Low-Hanging Fruit Approach. <i>Journal of Infectious Diseases</i> , 2019, 220, S7-S11.	4.0	13
39	Risk to bystanders in clinical trials: A symposium. <i>Clinical Trials</i> , 2019, 16, 447-449.	1.6	6
40	The importance of how research participants think they are perceived: results from an electronic monitoring study of antiretroviral therapy in Uganda. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 761-766.	1.2	9
41	Adding Lithium to Drinking Water for Suicide Prevention—The Ethics. <i>Public Health Ethics</i> , 2019, 12, 274-286.	1.0	14
42	What risk of death would people take to be cured of HIV and why? A survey of people living with HIV. <i>Journal of Virus Eradication</i> , 2019, 5, 109-115.	0.5	10
43	HIV Cure Research: Risks Patients Expressed Willingness to Accept. <i>Ethics &amp; Human Research</i> , 2019, 41, 23-34.	0.9	12
44	What risk of death would people take to be cured of HIV and why? A survey of people living with HIV. <i>Journal of Virus Eradication</i> , 2019, 5, 109-115.	0.5	6
45	What can the lived experience of participating in risky HIV cure-related studies establish?. <i>Journal of Medical Ethics</i> , 2018, 44, medethics-2017-104593.	1.8	10
46	Invited Commentary on DubÃ© et al. (Perceptions of Equipoise, Risk/Benefit Ratios, and “Otherwise) Tj ETQq0 0 0 rgBT /Overlock 10 Otherwise Healthy?. <i>Journal of Empirical Research on Human Research Ethics</i> , 2018, 13, 18-22.	1.3	2
47	Inequality in Political Philosophy and in Epidemiology: A Remarriage. <i>Journal of Applied Philosophy</i> , 2018, 35, 149-167.	1.0	2
48	Overcoming HIV Stigma? A Qualitative Analysis of HIV Cure Research and Stigma Among Men Who Have Sex with Men Living with HIV. <i>Archives of Sexual Behavior</i> , 2018, 47, 2061-2069.	1.9	16
49	Ethical issues in HIV remission trials. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 422-427.	3.8	22
50	Support for UNRWA's survival. <i>Lancet, The</i> , 2018, 392, 1009-1010.	13.7	0
51	Contact tracing performance during the Ebola epidemic in Liberia, 2014-2015. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006762.	3.0	90
52	Opinion: Risk to study nonparticipants: A procedural approach. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 8051-8053.	7.1	26
53	Ugandan Study Participants Experience Electronic Monitoring of Antiretroviral Therapy Adherence as Welcomed Pressure to Adhere. <i>AIDS and Behavior</i> , 2018, 22, 3363-3372.	2.7	12
54	Choices in vaccine trial design in epidemics of emerging infections. <i>PLoS Medicine</i> , 2018, 15, e1002632.	8.4	29

#	ARTICLE	IF	CITATIONS
55	Maximising the global health impact of future HIV cure-related interventions through advance planning. <i>Journal of Virus Eradication</i> , 2018, 4, 182-185.	0.5	2
56	Paying for antiretroviral adherence: is it unethical when the patient is an adolescent?. <i>Journal of Medical Ethics</i> , 2017, 43, 145-149.	1.8	7
57	How to keep high-risk studies ethical: classifying candidate solutions. <i>Journal of Medical Ethics</i> , 2017, 43, 74-77.	1.8	17
58	Vaccine testing for emerging infections: the case for individual randomisation. <i>Journal of Medical Ethics</i> , 2017, 43, 625-631.	1.8	12
59	Afterword: returning to philosophical foundations in research ethics. <i>Journal of Medical Ethics</i> , 2017, 43, 132-133.	1.8	0
60	When Ancillary Care Clashes with Study Aims. <i>New England Journal of Medicine</i> , 2017, 377, 1213-1215.	27.0	7
61	Improving vaccine trials in infectious disease emergencies. <i>Science</i> , 2017, 357, 153-156.	12.6	28
62	The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction. <i>Journal of Medical Ethics</i> , 2017, 43, 65-66.	1.8	28
63	Making Fair Choices on the Path to Universal Health Coverage: Applying Principles to Difficult Cases. <i>Health Systems and Reform</i> , 2017, 3, 301-312.	1.2	10
64	Coordinating Between Medical Professionsâ€™ Tasks to Optimize Sub-Saharan Health Systems: A Response to Recent Commentaries. <i>International Journal of Health Policy and Management</i> , 2017, 6, 123-125.	0.9	0
65	Ethical Issues in Disaster Medicine. , 2016, , 67-74.		3
66	Non-physician Clinicians in Sub-Saharan Africa and the Evolving Role of Physicians. <i>International Journal of Health Policy and Management</i> , 2016, 5, 149-153.	0.9	52
67	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016, 22, 839-850.	30.7	395
68	Incommensurability and Trade. <i>Monist, The</i> , 2016, 99, 387-405.	0.5	3
69	Is There a Moral Right to Nonmedical Vaccine Exemption?. <i>American Journal of Law and Medicine</i> , 2016, 42, 598-620.	0.2	6
70	Ethical Questions in Medical Electronic Adherence Monitoring. <i>Journal of General Internal Medicine</i> , 2016, 31, 338-342.	2.6	45
71	A staff support programme for rural hospitals in Nepal. <i>Bulletin of the World Health Organization</i> , 2016, 94, 65-70.	3.3	12
72	Three Case Studies in Making Fair Choices on the Path to Universal Health Coverage. <i>Health and Human Rights</i> , 2016, 18, 11-22.	1.3	7

#	ARTICLE	IF	CITATIONS
73	Standard of care versus second-best: Ethical dilemmas in surgery for high risk papillary thyroid cancer in low and middle-income countries. <i>Journal of Cancer Policy</i> , 2015, 6, 8-10.	1.4	2
74	HIV Treatment-As-Prevention Research: Authorsâ€™ Reply. <i>PLoS Medicine</i> , 2015, 12, e1001799.	8.4	2
75	Informed consent to participation in interventional studies: second-order in a different sense. <i>Journal of Law and the Biosciences</i> , 2015, 2, 123-128.	1.6	3
76	Ebola and beyond. <i>Science</i> , 2015, 348, 46-48.	12.6	18
77	Nudge, Embarrassment, and Restrictionâ€™ Replies to Voigt, Tieffenbach, and Saghai. <i>International Journal of Health Policy and Management</i> , 2015, 4, 53-54.	0.9	1
78	Nudging by Shaming, Shaming by Nudging. <i>International Journal of Health Policy and Management</i> , 2014, 3, 53-56.	0.9	23
79	HIV Treatment-as-Prevention Research at a Crossroads. <i>PLoS Medicine</i> , 2014, 11, e1001654.	8.4	18
80	Paternalism, French fries and the weak-willed Witness. <i>Journal of Medical Ethics</i> , 2014, 40, 353-354.	1.8	1
81	Informed consent, the value of trust, and hedons. <i>Journal of Medical Ethics</i> , 2014, 40, 447-447.	1.8	4
82	Using informed consent to save trust. <i>Journal of Medical Ethics</i> , 2014, 40, 437-444.	1.8	49
83	Pediatric heart surgery in Ghana: three ethical questions. <i>Journal of Clinical Ethics</i> , 2014, 25, 317-23.	0.3	3
84	Challenges in clinical trial design for HIV-1 cure research. <i>Lancet, The</i> , 2013, 382, 1464-1465.	13.7	37
85	Nudges and Noddges: The Ethics of Health Promotion--New York Style. <i>Public Health Ethics</i> , 2013, 6, 233-234.	1.0	3
86	Denial of Treatment to Obese Patientsâ€™the Wrong Policy on Personal Responsibility for Health. <i>International Journal of Health Policy and Management</i> , 2013, 1, 107-110.	0.9	24
87	Sticking with Carrots and Sticks (Sticking Points Aside): A Response to Ventakapuram, Goldberg, and Forrow. <i>International Journal of Health Policy and Management</i> , 2013, 1, 317-318.	0.9	0
88	Reconciling informed consent with prescription drug requirements. <i>Journal of Medical Ethics</i> , 2012, 38, 589-591.	1.8	7
89	Repeat Triage in Disaster Relief: Questions from Haiti. <i>PLOS Currents</i> , 2012, 4, e4fbbdec6279ec.	1.4	13
90	Why Treat Noncompliant Patients? Beyond the Decent Minimum Account. <i>Journal of Medicine and Philosophy</i> , 2011, 36, 572-588.	0.8	2

#	ARTICLE	IF	CITATIONS
91	Scaling up changes in doctors'™ education for rural retention: a comment on World Health Organization recommendations. <i>Bulletin of the World Health Organization</i> , 2011, 89, 83-83.	3.3	29
92	Is the Body Special? Review of Cécile Fabre, <i>Whose Body is it Anyway? Justice and the Integrity of the Person</i> . <i>Utilitas</i> , 2009, 21, 233-245.	0.5	12
93	Motivating Prevention: from Carrots and Sticks to "Carrots" and "Sticks". <i>AMA Journal of Ethics</i> , 2008, 10, 756-762.	0.7	7
94	"Perhaps the most important primary good": self-respect and Rawls'™s principles of justice. <i>Politics, Philosophy &amp; Economics</i> , 2005, 4, 195-219.	1.0	31
95	Input and output in distributive theory. <i>Nous</i> , 0, , .	2.2	1
96	Consent Requirements for Testing Health Policies: An Intercontinental Comparison of Expert Opinions. <i>Journal of Empirical Research on Human Research Ethics</i> , 0, , 155626462210767.	1.3	1
97	Research ethics and public trust in vaccines: the case of COVID-19 challenge trials. <i>Journal of Medical Ethics</i> , 0, , medethics-2021-108086.	1.8	0